Indication

As monotherapy for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH):

  • In patients with haemolysis with clinical symptom(s) indicative of high disease activity.
  • In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.

Medicine details

Medicine name:
crovalimab (Piasky)
SMC ID:
SMC2728
Pharmaceutical company
Roche
BNF chapter
Nutrition and blood
Submission type
Abbreviated
Publication due date:
13 January 2025